Well, so did we. If you're -- if we're estimating that the market is 30,000 biles, we're going to be very close to being able to -- from our API stockpile, generate almost 15,000 biles of finished dosage form.Your second question, the gross margin sustainability in the mid-60s. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Thank you.So let me take the last question first. Fast forward 20 years later, the drug, now manufactured by At the same time, patients who are in dire need of this therapy are being devastated by the price hike as Acthar is currently not covered by Medicare. Lives in Québec City, Canada. Over time they decline. So on the day we bought it, we picked up their revenues and gross profit. And so in theory, the product itself could be -- the supplemental could be approved within four months. This was derived by applying a 50% discount to the total addressable market as per pricing competition, and then assigning a 40% to 45% risk discount for lack of infantile spasms exposure, and finally dividing by two (as there will be 2 products on the market). Retirement But we've always been a value type of buyer. ANI has completed peptide mapping to identify the related peptides presence at greater than 0.1% in all process validation batches.The results demonstrate consistent peptide levels in all three commercial scale process validation batches, and indicate a manufacturing process that is well controlled and consistent. If the opportunity presents itself, would you still grow your generics business through consolidation or should we think of business development going forward really focused on sort of the injectable and specialty [Speech Overlap]Brandon, thanks for that question. We will continue to invest in commercial launch inventory and estimate spending an additional $11.5 million in 2020 for pig pituitaries, API and finished dosage form Cortrophin Gel. Stock Advisor launched in February of 2002. And so we want -- because we want to have our pipeline have some additional high risk, high reward opportunities alongside all of, what we call, more of a tuck-in opportunities that sort of fuel our -- that has fueled our growth from the time we have been public since time today. In addition, ANI is trading at mere 9x price-to-earnings (non-GAAP) and has a small $500 million market cap. Adjusted non-GAAP EBITDA is projected to be between $80 million and $86 million, or essentially flat as compared to the $83.2 million posted in 2019.Inherent in this guidance are the following. After all, the newsletter they have run for over a decade, David and Tom just revealed what they believe are the Bob Woodward talks Trump, NFL Sunday, Western wildfires: 5 things to know this weekendJobs that could grow during the pandemic and recession Is it incremental generic competition, customer mix, just what the dynamics there are and kind of why you're seeing a little bit more pressure at the margin?Steve, let me just [Indecipherable] question first and I'll like you first question. Let's conquer your financial goals together...faster. And it cost just as much money, if not more, to launch drugs, inventory builds and obviously, waiting for your receivable dollars from the wholesalers than it does maybe than to develop the drug. As an important part of our strategy, ANI intends to continue to acquire assets from time to time. BAUDETTE, Minn., March 24, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP), an emerging leader in the specialty pharmaceutical industry, today announced that it has submitted a prior approval supplement (PAS) to the Endocrinology Division at the FDA for re-commercialization of Purified Cortrophin ® Gel (Repository Corticotropin Injection USP) (80 U/mL). And from a calendarization, the remaining spend that we anticipate will occur principally in the -- call it, the first quarter of this year. But that's -- there's an immediate effect from Amerigen.Vancomycin and Bretylium, as I think both Steve and I spoke to, is a constant bill. [Operator Instructions] It is now my pleasure to turn today's program over to Mr. Arthur Przybyl. The Company has done a very, very good job over the years in terms of building the business through opportunistic acquisitions, about brand and generic products taking advantage of the distress and misery in the space. The third batch stability pull is today, and we expect this batch to yield results consistent with the other two batches.Additionally, we have validated commercial drug product manufacturing by bracketing two batch sizes to facilitate flexibility in order to conserve API needs and manufacture only what is needed to meet market demand. I mean, we do anticipate a significant contribution from the Amerigen portfolio.